ZIOPHARM Oncology Inc (NASDAQ:ZIOP)’s share price traded down 5.5% on Monday . The company traded as low as $4.16 and last traded at $4.30. 3,309,900 shares changed hands during mid-day trading, an increase of 148% from the average session volume of 1,335,318 shares. The stock had previously closed at $4.55.

A number of equities analysts recently weighed in on the company. ValuEngine cut ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Zacks Investment Research raised ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $5.25 price target on the stock in a research note on Friday. BidaskClub raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research note on Tuesday, August 8th. Finally, HC Wainwright set a $10.00 price target on ZIOPHARM Oncology and gave the stock a “buy” rating in a research note on Tuesday, August 1st. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $12.58.

ZIOPHARM Oncology (NASDAQ:ZIOP) last released its earnings results on Monday, November 6th. The biotechnology company reported ($0.13) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.13). The business had revenue of $1.60 million for the quarter, compared to analysts’ expectations of $1.66 million. During the same period last year, the firm earned ($0.11) EPS. The company’s revenue was up .0% compared to the same quarter last year. research analysts predict that ZIOPHARM Oncology Inc will post -0.54 earnings per share for the current year.

In other ZIOPHARM Oncology news, CEO Laurence James Neil Cooper bought 6,440 shares of the stock in a transaction on Wednesday, November 8th. The shares were bought at an average price of $4.68 per share, with a total value of $30,139.20. Following the purchase, the chief executive officer now directly owns 1,083,731 shares in the company, valued at approximately $5,071,861.08. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 10.40% of the company’s stock.

Large investors have recently added to or reduced their stakes in the business. Amalgamated Bank lifted its holdings in shares of ZIOPHARM Oncology by 12.9% during the 2nd quarter. Amalgamated Bank now owns 16,807 shares of the biotechnology company’s stock valued at $105,000 after buying an additional 1,924 shares during the last quarter. BB&T Securities LLC acquired a new stake in shares of ZIOPHARM Oncology during the 2nd quarter valued at about $112,000. Oppenheimer & Co. Inc. lifted its holdings in shares of ZIOPHARM Oncology by 50.0% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 18,000 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 6,000 shares during the last quarter. Adell Harriman & Carpenter Inc. acquired a new stake in shares of ZIOPHARM Oncology during the 3rd quarter valued at about $141,000. Finally, Principal Financial Group Inc. lifted its holdings in shares of ZIOPHARM Oncology by 7.5% during the 2nd quarter. Principal Financial Group Inc. now owns 24,046 shares of the biotechnology company’s stock valued at $150,000 after buying an additional 1,673 shares during the last quarter. 41.88% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.watchlistnews.com/ziopharm-oncology-inc-ziop-stock-price-down-5-5/1700994.html.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.